SOLARAZE

Compare SOLARAZE  to:
Compare
Compare

Generic Name for SOLARAZE

Diclofenac sodium 3%; gel; contains benzyl alcohol.

Legal Classification:

Rx

Pharmacological Class for SOLARAZE

NSAID.

Manufacturer of SOLARAZE

PharmaDerm

Indications for SOLARAZE

Actinic keratoses.

Adult dose for SOLARAZE

Apply to lesions twice daily for 60–90 days.

Children's dosing for SOLARAZE

Not recommended.

Contraindications for SOLARAZE

Aspirin allergy. 3rd trimester pregnancy.

Precautions for SOLARAZE

Avoid sun and UV light. GI ulcers or bleeding. Severe renal or hepatic impairment. Avoid eyes, and broken, infected, or inflamed skin. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for SOLARAZE

Minimize use of other topical products on treated area and of systemic NSAIDs.

Adverse Reactions for SOLARAZE

Pruritus, rash, contact dermatitis, dry skin, exfoliation, paresthesia, local pain/edema, photosensitivity.

How is SOLARAZE supplied?

Gel—100 g

Related Disease:

Actinic keratoses
Dermatological conditions, miscellaneous

Related Resources

Generic imiquimod cream approved

February 26, 2010

Fougera has announced that the FDA has approved a generic imiquimod cream 5%, the equivalent to Aldara (from Graceway Pharmaceuticals).

Mederma Stretch Marks Therapy available

February 17, 2010

Merz Pharmaceuticals has expanded its Mederma product line with the availability of Mederma Stretch Marks Therapy (Cepalin, hyaluronic acid, centella asiatica leaf extract) for the improvement of the appearance of stretch marks.

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

Phase 3 study of PEP005 gel for treatment of actinic keratoses

July 07, 2009

Peplin announced the completion of enrollment of its two Phase 3 trials for the use of PEP005 (ingenol mebutate) gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on head treatment areas, which include the face and scalp.